Editas Medicine Company Profile (NASDAQ:EDIT)

Analyst Ratings

Consensus Ratings for Editas Medicine (NASDAQ:EDIT) (?)
Ratings Breakdown: 3 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $33.75 (24.49% upside)

Analysts' Ratings History for Editas Medicine (NASDAQ:EDIT)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016Jefferies GroupReiterated RatingHold$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Morgan StanleyInitiated CoverageEqual -> Equal Weight$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016JPMorgan Chase & Co.Initiated CoverageNeutral$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016JMP SecuritiesInitiated CoverageOutperform$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Editas Medicine (NASDAQ:EDIT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/25/2016N/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/16/2016Q116($0.30)($0.80)$1.08 million$0.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/30/2016Q4($0.52)($4.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Editas Medicine (NASDAQ:EDIT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.44)($0.44)($0.44)
Q3 20161($0.55)($0.55)($0.55)
Q4 20161($0.60)($0.60)($0.60)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Editas Medicine (NASDAQ:EDIT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Editas Medicine (NASDAQ:EDIT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/8/2016James E FlynnInsiderBuy100,000$16.00$1,600,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Editas Medicine (NASDAQ:EDIT)
DateHeadline
07/22/16 03:42 PMFrom curing diseases to making designer babies, human gene editing is coming
07/19/16 09:02 PMStock Moving Lower for the Month; Investor Update on Editas Medicine Inc. (NASDAQ:EDIT) - Engelwood Daily
07/16/16 07:10 AMExperimental drug shows promise in treating postpartum depression - The Boston Globe
07/15/16 10:47 AMEditas Medicine Incorporated (NASDAQ:EDIT) Sellers Increased By 9.06% Their Shorts - Consumer Eagle
07/13/16 09:00 PM‘Right To Try’ Experimental Medications Stance May Be Adopted In Republican Platform
07/13/16 09:00 PMVC firm hires medical officer to boost drug development
07/13/16 03:56 PMVC firm hires a medical officer to boost drug development at its companies - The Boston Globe
07/13/16 03:56 PMMerck's Former Chief Medical Officer to Join Flagship Ventures - Bloomberg
07/13/16 07:40 AMVC firm hires medical officer to boost drug development - The Boston Globe
07/13/16 07:40 AMShares Losing Ground for the Month; Investor Alert on Editas Medicine Inc. (NASDAQ:EDIT) - Engelwood Daily
07/12/16 11:00 PMDr. Michael Rosenblatt Joins Flagship Ventures as Chief Medical Officer - [PR Newswire] - CAMBRIDGE, Mass., July 13, 2016 /PRNewswire/ -- Flagship Ventures today announced the appointment of industry veteran Michael Rosenblatt, M.D., to the new position of Chief Medical Officer. In this capacity, Dr. Rosenblatt will lead global clinical development and medical affairs for the organization. He will play a key role in Flagship's internal venture creation team during the conception and launch of the next generation of pioneering biotechnology companies as well as serve as an ongoing strategic resource for all companies in the Flagship ecosystem supporting their clinical development strategies. Dr. Rosenblatt joins Flagship from Merck, where he served as Executive Vice President and Chief Medical Officer since 2009.
07/11/16 08:33 AMJuno Therapeutics Inc (NASDAQ:JUNO) & Sprint Corp (NYSE:S) Stocks in Focus - Money News (press release)
07/08/16 07:48 AMPureTech Appoints Feng Zhang to Scientific Advisory Board and Expands Team and Advisory Group - Yahoo Finance
07/07/16 03:46 PMGlobal Herpes Simplex Virus (HSV) Infections Pipeline Market Review H1 2016
07/06/16 09:36 PMStock Tracking Down This Month; Investor Alert on Editas Medicine Inc. (NASDAQ:EDIT) - Engelwood Daily
07/05/16 08:29 AMResearch report explores the market study on cystic fibrosis - pipeline review, H1 2016
06/29/16 08:43 PMCompany Overview of Editas Medicine Inc.
06/28/16 03:43 PMStocks in Focus: Editas Medicine Inc. (NASDAQ:EDIT), Yahoo! Inc. (NASDAQ:YHOO), ORBCOMM, Inc. (NASDAQ ... - KC Register
06/24/16 12:28 PM​Another Mass. biotech plans to take the IPO plunge despite Brexit uncertainty -
06/23/16 02:43 PMCrispr Wins Key Approval to Fight Cancer in Human Trials
06/22/16 03:52 PMEditas Medicine Inc. (NASDAQ:EDIT) plummeted -7.04%: AT&T, Inc. (NYSE:T), Synergy Resources Corporation ... - KC Register
06/21/16 03:35 PMEditas Medicine Inc. (NASDAQ:EDIT) Dropped-5.14%: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), Superior Energy ... - KC Register
06/20/16 09:58 AMGlobal Synthetic Biology Market is expected to Grow more than US$ 38 Billion by 2020 - by Market Research Engine
06/19/16 08:11 AMGlobal Synthetic Biology Market is expected to Grow more than US$ 38 Billion by 2020 – by Market Research Engine
06/18/16 08:19 AMEditas Medicine (NASDAQ:EDIT) decreased -3.78%: Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Xcel Energy ... - KC Register
06/17/16 07:57 AM'Altered mosquito next malaria weapon', says Gates
06/16/16 09:00 PMGates Says Altered Mosquito Is Next Weapon to Fight Malaria (2)
06/16/16 08:06 AMDoes this company hold a key to unlock biotech's Goldilocks space dilemma?
06/16/16 08:06 AMTopsy-Turvy Day
06/06/16 07:06 AMBrokers Set Expectations for Editas Medicine Inc's Q2 2016 Earnings (EDIT) - Let Me Know About This
06/02/16 03:54 PMSynthetic Biology Market Share,Supply and Consumption Market Report to 2020 - Scientific genomics Inc. Editas Medicine, Inc., Pareto Biotechnologies, Blue heron, TeselaGen, Twist biosciences, Syntrox Inc., and others. This report provides an extensive analysis of the current and emerging market trends and dynamics in the world ...
06/02/16 08:05 AMTop Analyst Upgrades and Downgrades: Deutsche Bank, Editas, EMC, Exxon Mobil, First Solar, Newmont Mining and More -
05/28/16 11:20 AMEditas Medicine Incorporated (NASDAQ:EDIT) Shorted Shares Decreased By 1.66% - HNN - Editas Medicine Incorporated (NASDAQ:EDIT) Shorted Shares Decreased By 1.66%HNNEditas Medicine, Inc., formerly Gengine, Inc., is a genome editing company. The company has a market cap of $1.27 billion. The Firm is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It ...
05/25/16 04:39 PMEditas Medicine Inc (NASDAQ:EDIT) Stock Update & Estimates - Stock Tick Tock - Editas Medicine Inc (NASDAQ:EDIT) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Editas Medicine Inc (NASDAQ:EDIT) to post earnings of $-0.47 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued ...and more »
05/25/16 07:22 AMEditas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : May 25, 2016 -
05/24/16 04:43 PMEditas Medicine to Present at Upcoming June Investor Conferences - Virtual-Strategy Magazine - Editas Medicine to Present at Upcoming June Investor ConferencesVirtual-Strategy MagazineEditas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate ...
05/24/16 03:26 PMEditas Medicine to Present at Upcoming June Investor Conferences - [at noodls] - CAMBRIDGE, Mass., May 24, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present company overviews at three upcoming investor ...
05/23/16 07:05 AM10 Speculative Biotech and BioHealth Stocks With Massive Analyst Upside Calls -
05/22/16 04:45 PMRevenue Update on Editas Medicine, Inc. - Common Stock(NASDAQ:EDIT) - Trade Calls - Trade CallsRevenue Update on Editas Medicine, Inc. - Common Stock(NASDAQ:EDIT)Trade CallsEditas Medicine, Inc. – Common Stock(NASDAQ:EDIT) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 16, 2016. Company reported revenue of $805.00K. Analysts estimated a revenue of $1.08M.and more »
05/20/16 12:04 PMEDITAS MEDICINE, INC. Financials -
05/17/16 04:47 PMEarnings Alert: Editas Medicine Inc (NASDAQ:EDIT) - The Point Review - The Point ReviewEarnings Alert: Editas Medicine Inc (NASDAQ:EDIT)The Point ReviewEditas Medicine Inc (NASDAQ:EDIT) shares traded during its most recent trading session in the range of $30.89 – $36.24. The stock has climbed 12.21% in the past week and plunged -14.72% in the last 4 weeks, historically the stock illustrate that its ...Janney Remains Bullish on Editas Medicine24/7 Wall St.Editas Medicine Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Advance New CRISPR/Cas9 ...NasdaqEditas Medicine Signs Deal with Cystic Fibrosis Foundation Therapeutics to Treat CF; Shares Rise 6% Early (NASDAQ ...Sonoran Weekly ReviewGlobeNewswire (press release) -Benchmark Monitor -Risers & Fallersall 19 news articles »
05/16/16 04:33 PMBRIEF-Editas Medicine Q1 loss per share $0.80 - Reuters - BRIEF-Editas Medicine Q1 loss per share $0.80ReutersBRIEF-Editas Medicine Q1 loss per share $0.80. May 16 Editas Medicine Inc. * Editas medicine announces first quarter 2016 results and update. * Q1 loss per share $0.80 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: ...
05/16/16 04:33 PMJanney Remains Bullish on Editas Medicine - 24/7 Wall St. - 24/7 Wall St.Janney Remains Bullish on Editas Medicine24/7 Wall St.Editas Medicine Inc. (NASDAQ: EDIT) has become a rather interesting stock for many speculative biotech and biohealth investors. It has also been quite volatile. Its shares were trading higher on Monday after the release of its quarterly results and ...Editas Medicine Announces First Quarter 2016 Results and UpdateGlobeNewswire (press release)Editas Medicine Posts Wider Q1 Loss Vs. Street, Misses on Revenue (NASDAQ:EDIT)Sonoran Weekly ReviewEditas Medicine, Inc. (NASDAQ:EDIT) Expected To Report Earnings On MondayRisers & FallersFranklin Independent -Seeking Alpha -Boston Business Journal (blog)all 14 news articles »
05/16/16 03:12 PMEdited Transcript of EDIT earnings conference call or presentation 16-May-16 12:30pm GMT -
05/16/16 11:15 AMJanney Remains Bullish on Editas Medicine -
05/16/16 07:30 AMEditas Medicine Inc Earnings Call (Q1 2016) - Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. It is developing a proprietary genome editing platform based on CRISPR/Cas9 technology ...
05/16/16 07:30 AMEDITAS MEDICINE, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - On May 16, 2016, Editas Medicine, Inc., a Delaware corporation (the "Company"), issued a press release announcing financial results for the fiscal quarter ended March 31, 2016. A copy of the press release is being furnished as Exhibit 99.1 to this Current ...
05/16/16 07:19 AMEditas Medicine Inc Earnings Call scheduled for 8:30 am ET today -
05/16/16 06:47 AMEDITAS MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh -
05/16/16 06:42 AMEditas Medicine Announces First Quarter 2016 Results and Update - [at noodls] - Advancing pipeline and platform demonstrated by data presented at medical and scientific conferences as well as achievement of Juno Therapeutics milestone Strengthened effort to develop medicines for cystic ...

Social

About Editas Medicine

Editas Medicine logoEditas Medicine, Inc., formerly Gengine, Inc., is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology. CRISPR/Cas9 uses a protein ribonucleic acid (RNA) complex consisting of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence that requires repair. The Company has initiated a range of research programs across multiple therapeutic areas. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs, including Non-malignant Hematologic Diseases, Duchenne Muscular Dystrophy, Cystic Fibrosis and Alpha-1 Antitrypsin Deficiency.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EDIT
  • CUSIP:
Key Metrics:
  • Previous Close: $25.84
  • 50 Day Moving Average: $27.73
  • 200 Day Moving Average: $30.28
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $954.38M
  • Current Year EPS Consensus Estimate: $-2.07 EPS
  • Next Year EPS Consensus Estimate: $-2.29 EPS
Additional Links:
Editas Medicine (NASDAQ:EDIT) Chart for Saturday, July, 23, 2016